CRF2 receptor-deficiency eliminates opiate withdrawal distress without impairing stress coping

Molecular Psychiatry

Volumn 17, Issue 12, 2012, Pages 1283-1294

  Ingallinesi, M ^a   Rouibi, K ^a   Le Moine, C ^a   Papaleo, F ^a,b   Contarino, A ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

corticotropin releasing factor system; CRF2 receptor pathway; negative affect; opiate withdrawal distress; stress coping

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; MORPHINE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DYNORPHIN; TYROSINE 3 MONOOXYGENASE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; DYSPHORIA; FEMALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; WITHDRAWAL SYNDROME; ADAPTIVE BEHAVIOR; ADDICTION; ANIMAL; BIOSYNTHESIS; BLOOD; BRAIN; C57BL MOUSE; DISEASE MODEL; GENETICS; MENTAL STRESS; METABOLISM; MOUSE MUTANT; OPIATE ADDICTION; PSYCHOLOGICAL ASPECT;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; DYNORPHINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OPIOID-RELATED DISORDERS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; TYROSINE 3-MONOOXYGENASE;

EID: 84870053879     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.119     Document Type: Article

References (50)

1. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006; 81: 103-107.
2. APA. American Psychiatric Association. Diagnostic and Statistical Manual ofMental Disorders, 4th Edition, Text Revised (DSM-IV-TR). Washington DC, 2000.
3. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 2006; 26: 5894-5900.
4. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 2005; 8: 1442-1444.
5. Koob GF. A role for brain stress systems in addiction. Neuron 2008; 59: 11-34.
6. Nutt D, Lingford-Hughes A. Addiction: the clinical interface. Br J Pharmacol 2008; 154: 397-405.
7. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5: 374-381.
8. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999; 46: 1167-1180.
9. Rivier C, Brownstein M, Spiess J, Rivier J, Vale W. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology 1982; 110: 272-278.
10. Valentino RJ, Van Bockstaele E. Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur J Pharmacol 2008; 583: 194-203.
11. Erb S, Shaham Y, Stewart J. The role of corticotropin-releasing factor and corticosterone in stress-and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 1998; 18: 5529-5536.
12. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y. The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 2000; 150: 317-324.
13. Funk CK, O'Dell LE, Crawford EF, Koob GF. Corticotropinreleasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 2006; 26: 11324-11332.
14. Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 1993; 605: 25-32.
15. Maj M, Turchan J, Smialowska M, Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003; 37: 105-110.
16. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF et al. Increase of extracellular corticotropinreleasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15: 5439-5447.
17. Olive MF, Koenig HN, Nannini MA, Hodge CW. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 2002; 72: 213-220.
18. Richter RM, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 1999; 32: 254-261.
19. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropinreleasing factor and their ligands. Pharmacol Rev 2003; 55: 21-26.
20. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24: 410-414.
21. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24: 403-409.
22. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24: 415-419.
23. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093-1102.
24. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19: 162-166.
25. Papaleo F, Ghozland S, Ingallinesi M, Roberts AJ, Koob GF, Contarino A. Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology 2008; 33: 2878-2887.
26. Papaleo F, Kitchener P, Contarino A. Disruption of the CRF/CRF(1) receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 2007; 53: 577-589.
27. Contarino A, Papaleo F. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 2005; 102: 18649-18654.
28. Frenois F, Stinus L, Di Blasi F, Cador M, Le Moine C. A specific limbic circuit underlies opiate withdrawal memories. J Neurosci 2005; 25: 1366-1374.
29. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. Academic Press: San Diego, 2001.
30. Juaneda C, Lafon-Dubourg P, Ciofi P, Sarrieau A, Wenger T, Tramu G et al. CCK mRNA expression in neuroendocrine CRH neurons is increased in rats subjected to an immune challenge. Brain Res 2001; 901: 277-280.
31. Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur J Neurosci 1999; 11: 481-490.
32. Papaleo F, Contarino A. Gender-and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. Behav Brain Res 2006; 170: 110-118.
33. Funada M, Suzuki T, Narita M, Misawa M, Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 1993; 32: 1315-1323.
34. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982; 215: 413-415.
35. Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991; 104: 255-259.
36. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988; 244: 1067-1080.
37. Mark GP, Blander DS, Hoebel BG. A conditioned stimulus decreases extracellular dopamine in the nucleus accumbens after the development of a learned taste aversion. Brain Res 1991; 551: 308-310.
38. Morgan JI, Curran T. Immediate-early genes: ten years on. Trends Neurosci 1995; 18: 66-67.
39. Koob GF, Maldonado R, Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992; 15: 186-191.
40. Markey KA, Sze PY. Influence of ACTH on tyrosine hydroxylase activity in the locus coeruleus of mouse brain. Neuroendocrinology 1984; 38: 269-275.
41. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008; 28: 407-414.
42. Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 2009; 106: 19168-19173.
43. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 1995; 6: 74-80.
44. Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M et al. Corticotropin releasing factor-induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol Psychiatry 2010; 67: 831-839.
45. Fekete EM, Zhao Y, Szucs A, Sabino V, Cottone P, Rivier J et al. Systemic urocortin 2, but not urocortin 1 Or stressin(1)-A, suppresses feeding via Crf(2) receptors without malaise and stress. Br J Pharmacol 2011; 2011: 1476-5381.
46. Krahn DD, Gosnell BA, Levine AS, Morley JE. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res 1988; 443: 63-69.
47. Melia KR, Duman RS. Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. Proc Natl Acad Sci USA 1991; 88: 8382-8386.
48. Page ME, Abercrombie ED. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse 1999; 33: 304-313.
49. Smagin GN, Swiergiel AH, Dunn AJ. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res Bull 1995; 36: 71-76.
50. Raber J, Koob GF, Bloom FE. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J Pharmacol Exp Ther 1995; 272: 815-824.